The FDA's conditional approval for Lumakras (sotorasib; formerly AMG-510) as a second-line treatment for KRAS G12c-mutated non-small cell lung cancer (NSCLC) has come more than two months ahead of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback